1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Zimbabwe Pharmaceuticals and Healthcare Report Q2 2016

Zimbabwe Pharmaceuticals and Healthcare Report Q2 2016

  • April 2016
  • -
  • Business Monitor International
  • -
  • 69 pages

Includes 3 FREE quarterly updates

BMI View: Zimbabwe's health sector will deteriorate over the short term as a result of significant cuts tonational budget allocations. Despite the distribution to healthcare growing over the last seven years, itremains far from meeting the global commitment agreed in Abuja in 2001 of 15% of the national budget.Government revenue earning capabilities have declined as Zimbabwe's main exports are suffering fromlower commodity prices, as well as diminishing taxable income from stagnant economic growth. This willnegatively affect Zimbabwe's healthcare delivery over the short term. Over the long term, continuedreliance on foreign aid will discourage investment from drugmakers.Headline Expenditure ProjectionsPharmaceuticals: USD380mn in 2015 to USD399mn in 2016; +5.0% in US dollar terms. Forecastunchanged from last quarter.

Table Of Contents

Zimbabwe Pharmaceuticals and Healthcare Report Q2 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Zimbabwe 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Zimbabwe 2012-2020) 13
Healthcare Market Forecast 14
Prescription Drug Market Forecast 16
Patented Drug Market Forecast 17
Generic Drug Market Forecast 18
Pharmaceutical Trade Forecast 19
Table: Pharmaceutical Trade Data And Forecasts (Zimbabwe 2014-2020) 21
Industry Risk/Reward Index 22
Middle East and Africa Risk/Reward Index - Q2 2016 22
Zimbabwe Risk/Reward Index 29
Rewards 29
Risks 29
Regulatory Review 31
Regulatory Regime 31
Intellectual Property Issues 33
Pricing And Reimbursement Regime 34
Market Overview 37
Healthcare Sector 38
Table: Zimbabwe: Healthcare Facilities 38
Healthcare Funding 40
Research and Development 44
Clinical Trials 45
Epidemiology 45
Competitive Landscape 48
Table: Multinational Market Activity 51
Pharmaceutical Retail Sector 51
Company Profile 53
Datlabs 53
Varichem Laboratories 55
Demographic Forecast 58
Table: Population Headline Indicators (Zimbabwe 1990-2025) 59
Table: Key Population Ratios (Zimbabwe 1990-2025) 59
Table: Urban/Rural Population and Life Expectancy (Zimbabwe 1990-2025) 60
Table: Population By Age Group (Zimbabwe 1990-2025) 60
Table: Population By Age Group % (Zimbabwe 1990-2025) 61
Glossary 63
Methodology 65
Pharmaceutical Expenditure Forecast Model 65
Healthcare Expenditure Forecast Model 65
Notes On Methodology 66
Risk/Reward Index Methodology 67
Index Overview 68
Table: Pharmaceutical Risk/Reward Index Indicators 68
Indicator Weightings 69

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.